Showing results (331-340 of 731) with videos related to
Sort By:
Pageof 74
European Journal of Cancer (Oxford, England : 1990)|August 30, 2025
Uveal Melanoma UK national guidelines: 2023 updateThomas J Carter, Jack Broadfoot, Sarah E Coupland, et al.Journal for Immunotherapy of Cancer|June 14, 2020
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategyJohn Haanen, Marc Ernstoff, Yinghong Wang, et al.American Journal of Clinical Oncology|January 30, 2013
Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomesJames Larkin, Mayer Fishman, Laura Wood, et al.Clinical Trials (London, England)|January 25, 2025
NHS-Galleri trial: Enriched enrolment approaches and sociodemographic characteristics of enrolled participantsCharles Swanton, Velicia Bachtiar, Chris Mathews, et al.Expert Opinion on Pharmacotherapy|December 22, 2012
Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysisJames Larkin, Abby Paine, Indra Tumur, et al.Cancer Chemotherapy and Pharmacology|November 6, 2013
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)Ana M Molina, Thomas E Hutson, James Larkin, et al.Cancer Cell|April 16, 2015
Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signalingEishu Hirata, Maria Romina Girotti, Amaya Viros, et al.Nature Communications|July 17, 2024
Replication timing alterations are associated with mutation acquisition during breast and lung cancer evolutionMichelle Dietzen, Haoran Zhai, Olivia Lucas, et al.Cancer Cell|October 29, 2021
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinomaLewis Au, Emine Hatipoglu, Marc Robert de Massy, et al.European Urology Open Science|June 17, 2026
Corrigendum to "Long-term real-world survival outcomes with dual immune checkpoint blockade in synchronous metastatic renal cell carcinoma: implications for the design of prospective cytoreductive nephrectomy trials" [Eur. Urol. Open Sci. 83 (2026) 133-141]Leo Bickley, Elisabeth E Fransen van de Putte, Luna van den Brink, et al.Pageof 74